Embracing Monogenic Parkinson's Disease: the MJFF Global Genetic PD Cohort.
Eva-Juliane Vollstedt,Susen Schaake,Katja Lohmann,Shalini Padmanabhan,Alexis Brice,Suzanne Lesage,Christelle Tesson,Marie Vidailhet,Isabel Wurster,Faycel Hentati,Anat Mirelman,Nir Giladi,Karen Marder,Cheryl Waters,Stanley Fahn,Meike Kasten,Norbert Bruggemann,Max Borsche,Tatiana Foroud,Eduardo Tolosa,Alicia Garrido,Grazia Annesi,Monica Gagliardi,Maria Bozi,Leonidas Stefanis,Joaquim J. Ferreira,Leonor Correia Guedes,Micol Avenali,Simona Petrucci,Lorraine Clark,Ekaterina Y. Fedotova,Natalya Y. Abramycheva,Victoria Alvarez,Manuel Menendez-Gonzalez,Silvia Jesus Maestre,Pilar Gomez-Garre,Pablo Mir,Andrea Carmine Belin,Caroline Ran,Chin-Hsien Lin,Ming-Che Kuo,David Crosiers,Zbigniew K. Wszolek,Owen A. Ross,Joseph Jankovic,Kenya Nishioka,Manabu Funayama,Jordi Clarimon,Caroline H. Williams-Gray,Marta Camacho,Mario Cornejo-Olivas,Luis Torres-Ramirez,Yih-Ru Wu,Guey-Jen Lee-Chen,Ana Morgadinho,Teeratorn Pulkes,Pichet Termsarasab,Daniela Berg,Gregor Kuhlenbaumer,Andrea A. Kuhn,Friederike Borngraeber,Giuseppe de Michele,Anna De Rosa,Alexander Zimprich,Andreas Puschmann,George D. Mellick,Jolanta Dorszewska,Jonathan Carr,Rosangela Ferese,Stefano Gambardella,Bruce Chase,Katerina Markopoulou,Wataru Satake,Tatsushi Toda,Malco Rossi,Marcelo Merello,Timothy Lynch,Diana A. Olszewska,Shen-Yang Lim,Azlina Ahmad-Annuar,Ai Huey Tan,Bashayer Al-Mubarak,Hasmet Hanagasi,Dariusz Koziorowski,Sibel Ertan,Gencer Genc,Patricia de Carvalho Aguiar,Melinda Barkhuizen,Marcia M. G. Pimentel,Rachel Saunders-Pullman,Bart van de Warrenburg,Susan Bressman,Mathias Toft,Silke Appel-Cresswell,Anthony E. Lang,Matej Skorvanek,Agnita J. W. Boon,Rejko Kruger,Esther M. Sammler,Vitor Tumas,Bao-Rong Zhang,Gaetan Garraux,Sun Ju Chung,Yun Joong Kim,Juliane Winkelmann,Carolyn M. Sue,Eng-King Tan,Joana Damasio,Peter Klivenyi,Vladimir S. Kostic,David Arkadir,Mika Martikainen,Vanderci Borges,Jens Michael Hertz,Laura Brighina,Mariana Spitz,Oksana Suchowersky,Olaf Riess,Parimal Das,Brit Mollenhauer,Emilia M. Gatto,Maria Skaalum Petersen,Nobutaka Hattori,Ruey-Meei Wu,Sergey N. Illarioshkin,Enza Maria Valente,Jan O. Aasly,Anna Aasly,Roy N. Alcalay,Avner Thaler,Matthew J. Farrer,Kathrin Brockmann,Jean-Christophe Corvol,Christine Klein
DOI: https://doi.org/10.1002/mds.29288
IF: 9.698
2023-01-01
Movement Disorders
Abstract:Background: As gene-targeted therapies are increasingly being developed for Parkinson's disease (PD), identifying and characterizing carriers of specific genetic pathogenic variants is imperative. Only a small fraction of the estimated number of subjects with monogenic PD worldwide are currently represented in the literature and availability of clinical data and clinical trial-ready cohorts is limited. ObjectiveThe objectives are to (1) establish an international cohort of affected and unaffected individuals with PD-linked variants; (2) provide harmonized and quality-controlled clinical characterization data for each included individual; and (3) further promote collaboration of researchers in the field of monogenic PD. Methods: We conducted a worldwide, systematic online survey to collect individual-level data on individuals with PD-linked variants in SNCA, LRRK2, VPS35, PRKN, PINK1, DJ-1, as well as selected pathogenic and risk variants in GBA and corresponding demographic, clinical, and genetic data. All registered cases underwent thorough quality checks, and pathogenicity scoring of the variants and genotype-phenotype relationships were analyzed. Results: We collected 3888 variant carriers for our analyses, reported by 92 centers (42 countries) worldwide. Of the included individuals, 3185 had a diagnosis of PD (ie, 1306 LRRK2, 115 SNCA, 23 VPS35, 429 PRKN, 75 PINK1, 13 DJ-1, and 1224 GBA) and 703 were unaffected (ie, 328 LRRK2, 32 SNCA, 3 VPS35, 1 PRKN, 1 PINK1, and 338 GBA). In total, we identified 269 different pathogenic variants; 1322 individuals in our cohort (34%) were indicated as not previously published. Conclusions: Within the MJFF Global Genetic PD Study Group, we (1) established the largest international cohort of affected and unaffected individuals carrying PD-linked variants; (2) provide harmonized and quality-controlled clinical and genetic data for each included individual; (3) promote collaboration in the field of genetic PD with a view toward clinical and genetic stratification of patients for gene-targeted clinical trials. (c) 2023 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.